Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Esperion Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $18.8 million, net income net losses of $55.5 million for the fourth quarter of 2022 and $233.7 million for the full year ended December 31, 2022, EPS basic and diluted net losses per share of $0.76 for the fourth quarter of 2022 and $3.52 for the year ended December 31,.
- Period
- the fourth quarter and full year ended December 31, 2022
- Revenue
- $18.8 million
- Net income
- net losses of $55.5 million for the fourth quarter of 2022 and $233.7 million for the full year ended December 31, 2022
- EPS
- basic and diluted net losses per share of $0.76 for the fourth quarter of 2022 and $3.52 for the year ended December 31,
- Result
- reported results
Exact text from the filing
consumer and brand awareness in their national fanbase Fourth Quarter and Full Year 2022 Financial Results Total revenue for the fourth quarter ended December 31, 2022, was $18.8 million and $75.5 million for the full year ended December 31, 2022, compared to $15.4 million and $78.4 million for the comparable periods in 2021, an increase of 22% and a decrease of
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Esperion Therapeutics, Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023 (effective 2023-02-21).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Jefferies LLC
- Value
- the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023
- Effective
- 2023-02-21
Exact text from the filing
In connection with the Company’s entry into the 2023 Sales Agreement, the Company terminated the 2021 Sales Agreement, effective as of February 21, 2023, pursuant to Section 7(b)(i) thereof.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Esperion Therapeutics, Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at up to $70,000,000 of shares of the Company's common stock (effective 2023-02-21).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Cantor Fitzgerald & Co.
- Value
- up to $70,000,000 of shares of the Company's common stock
- Effective
- 2023-02-21
Exact text from the filing
On February 21, 2023, Esperion Therapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “2023 Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $70,000,000 of shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as the Company’s sales agent (the “ATM Offering”).
View on SEC.gov